IP Library Granted Patent US 8,759,504
Granted Patent B2
US 8,759,504 · App. 13/367,102 · Granted Jun 24, 2014

Cholinergic/serotoninergic receptor and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,759,504
App. No.
13/367,102
Granted
Jun 24, 2014
Kind
B2
Abstract

The present invention describes new cholinergic/serotoninergic chimeric receptors and provides methods and compositions suitable for screening for ligands such as agonists, antagonists and allosteric modulators of α7 nicotinic acetylcholine receptors.

Claims (10)

1. A recombinant nucleic acid encoding a cholinergic/serotoninergic chimeric receptor, wherein the nucleic acid comprises SEQ ID NO:2.

2. The nucleic acid of claim 1 , wherein the nucleic acid encodes a polypeptide having an amino acid sequence as set forth in SEQ ID NO:10.

3. A vector comprising the recombinant nucleic acid of claim 1 .

4. The vector of claim 3 , wherein the recombinant nucleic acid is operably linked to control sequences recognized by a host cell transformed with the vector.

5. A host cell comprising the vector of claim 4 .

6. A method of producing a cholinergic/serotoninergic chimeric receptor comprising transforming a host cell with the vector of claim 3 .

7. A method for identifying a ligand to a cholinergic/serotoninergic chimeric receptor comprising the amino acid sequence of SEQ ID NO:10, wherein the method comprises contacting the cholinergic/serotoninergic chimeric receptor with a test compound, or a test compound and a positive allosteric modulator, and measuring a response of the cholinergic/serotoninergic chimeric receptor to the test compound, wherein a measurable response of the cell indicates that the test compound is a ligand to the cholinergic/serotoninergic chimeric receptor.

8. The method of claim 7 , wherein the cholinergic/serotoninergic chimeric receptor's response to the compound is measured by a binding assay or an electrophysiological assay.

9. The method of claim 7 , wherein the compound is selected from the group consisting of a human neuronal nicotinic cholinergic α7 agonist and a human neuronal nicotinic cholinergic α7 antagonist.

10. The method of claim 7 , wherein the positive allosteric modulator is a type I positive allosteric modulator or a type II positive allosteric modulator.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2013
From: ABBOTT LABORATORIES
To: ABBVIE INC.
Reel/Frame 030235/0856 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2012
From: GOPALAKRISHNAN, MURALI; LI, JINHE; CASSAR, STEVEN C.; MALYSZ, JOHN; ANDERSON, DAVID J.; GUBBINS, EARL J.; BERTRAND, DANIEL C.
To: ABBOTT LABORATORIES
Reel/Frame 028164/0332 →